Entrada Therapeutics, Inc. (TRDA)
$7.00-$0.27 (-3.71%) Today
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 15 | 576,442 | $4.05M |
| Grant or award | 6 | 114,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
46 Form 4 filings on record, the earliest from Oct 18, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. - 10% Owner | Open-market sale | Common Stock | 21,623 | $7.34 | $159K | |
| MPM BioVentures 2014, L.P. - 10% Owner | Open-market sale | Common Stock | 26,522 | $7.54 | $200K | |
| MPM BioVentures 2014, L.P. - 10% Owner | Open-market sale | Common Stock | 14,569 | $7.06 | $103K | |
| MPM BIOVENTURES 2018, L.P. - 10% Owner | Open-market sale | Common Stock | 21,623 | $7.34 | $159K | |
| MPM BIOVENTURES 2018, L.P. - 10% Owner | Open-market sale | Common Stock | 26,522 | $7.54 | $200K | |
| MPM BIOVENTURES 2018, L.P. - 10% Owner | Open-market sale | Common Stock | 14,569 | $7.06 | $103K | |
| Kush Parmar - Director | Open-market sale | Common Stock | 10,494 | $7.00 | $73K | |
| Kush Parmar - Director | Open-market sale | Common Stock | 52,317 | $6.85 | $358K | |
| Kush Parmar - Director | Open-market sale | Common Stock | 92,444 | $7.00 | $647K | |
| 5AM Ventures V, L.P. - 10% Owner | Open-market sale | Common Stock | 10,494 | $7.00 | $73K | |
| 5AM Ventures V, L.P. - 10% Owner | Open-market sale | Common Stock | 52,317 | $6.85 | $358K | |
| 5AM Ventures V, L.P. - 10% Owner | Open-market sale | Common Stock | 114,756 | $6.93 | $795K | |
| 5AM Ventures V, L.P. - 10% Owner | Open-market sale | Common Stock | 1,718 | $6.85 | $12K | |
| Kush Parmar - Director | Open-market sale | Common Stock | 114,756 | $6.93 | $795K | |
| Kush Parmar - Director | Open-market sale | Common Stock | 1,718 | $6.85 | $12K | |
| Kush Parmar - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| Peter S. Kim - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
 Gina Chapman - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
 Maha Radhakrishnan - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
 Mary Thistle - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| Bernhardt G. Zeiher - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| Bernhardt G. Zeiher - Director | Open-market purchase | Common Stock | 5,000 | $5.86 | $29K | |
| Natarajan Sethuraman - Officer | Open-market sale | Common Stock | 25,907 | $15.39 | $399K | |
| Nathan J. Dowden - Officer | Option exercise | Common Stock | 15,000 | $1.74 | $26K | |
| Nathan J. Dowden - Officer | Open-market sale | Common Stock | 15,000 | $15.33 | $230K | |
| Nathan J. Dowden - Officer | Option exercise | Stock Option (Right to Buy) | 15,000 | $0.00 | - | |
| Kory James Wentworth - Officer | Open-market sale | Common Stock | 2,500 | $12.95 | $32K | |
| Nathan J. Dowden - Officer | Open-market sale | Common Stock | 3,116 | $13.02 | $41K | |
| Nathan J. Dowden - Officer | Open-market sale | Common Stock | 11,894 | $13.05 | $155K | |
| Kory James Wentworth - Officer | Open-market sale | Common Stock | 5,089 | $13.00 | $66K | |
| Kory James Wentworth - Officer | Open-market sale | Common Stock | 11,388 | $13.02 | $148K | |
| Kory James Wentworth - Officer | Open-market sale | Common Stock | 7,988 | $12.25 | $98K | |
| Dipal Doshi - Officer | Grant or award | Common Stock | 139,400 | $0.00 | - | |
| Dipal Doshi - Officer | Tax withholding / forfeiture | Common Stock | 9,869 | $11.66 | $115K | |
| Dipal Doshi - Officer | Tax withholding / forfeiture | Common Stock | 19,181 | $11.76 | $225K | |
| Dipal Doshi - Officer | Grant or award | Stock Option (Right to Buy) | 208,000 | $0.00 | - | |
| Kory James Wentworth - Officer | Grant or award | Stock Option (Right to Buy) | 66,600 | $0.00 | - | |
| Kory James Wentworth - Officer | Grant or award | Common Stock | 44,600 | $0.00 | - | |
| Kory James Wentworth - Officer | Tax withholding / forfeiture | Common Stock | 2,939 | $11.66 | $34K | |
| Kory James Wentworth - Officer | Tax withholding / forfeiture | Common Stock | 5,712 | $11.76 | $67K | |
| Nathan J. Dowden - Officer | Tax withholding / forfeiture | Common Stock | 14,038 | $11.76 | $165K | |
| Nathan J. Dowden - Officer | Grant or award | Stock Option (Right to Buy) | 83,200 | $0.00 | - | |
| Nathan J. Dowden - Officer | Grant or award | Common Stock | 55,800 | $0.00 | - | |
| Nathan J. Dowden - Officer | Tax withholding / forfeiture | Common Stock | 7,223 | $11.66 | $84K | |
| Natarajan Sethuraman - Officer | Grant or award | Stock Option (Right to Buy) | 83,200 | $0.00 | - | |
| Natarajan Sethuraman - Officer | Grant or award | Common Stock | 55,800 | $0.00 | - | |
| Natarajan Sethuraman - Officer | Tax withholding / forfeiture | Common Stock | 3,898 | $11.66 | $45K | |
| Natarajan Sethuraman - Officer | Tax withholding / forfeiture | Common Stock | 7,577 | $11.76 | $89K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 1,213 | $9.07 | $11K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 13,386 | $9.07 | $121K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 1,186 | $9.07 | $11K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 13,082 | $9.07 | $119K | |
| Kory James Wentworth - Officer | Open-market sale | Common Stock | 8,910 | $9.98 | $89K | |
| Kush Parmar | Open-market sale | Common Stock | 200,000 | $8.80 | $1.76M | |
| 5AM Ventures V, L.P. | Open-market sale | Common Stock | 200,000 | $8.80 | $1.76M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 2,296 | $7.21 | $17K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 25,364 | $7.21 | $183K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 267 | $7.22 | $2K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 2,947 | $7.22 | $21K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 1,059 | $7.39 | $8K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 11,701 | $7.39 | $86K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 2,795 | $7.54 | $21K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 30,879 | $7.54 | $233K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 7,321 | $7.73 | $57K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 80,881 | $7.73 | $625K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 1,040 | $7.95 | $8K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 11,494 | $7.95 | $91K | |
| Natarajan Sethuraman - Officer | Tax withholding / forfeiture | Common Stock | 1,760 | $5.43 | $10K | |
| Dipal Doshi - Officer | Tax withholding / forfeiture | Common Stock | 8,723 | $5.43 | $47K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| 5AM Ventures V, L.P. | Affiliated stockholder | 165,578 | $1.08M | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Entrada Therapeutics, Inc. (TRDA) had 12 insider filings in the last 90 days, with the most recent on 2026-08-27. The full record for TRDA runs to 46 Form 4 filings, the earliest from 2024-10-18. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TRDA were filed in the last 90 days. 19 purchases are on record for this company.
15 insider sales of TRDA were filed in the last 90 days, totaling $4.05M.
This page tracks TRDA Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TRDA to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
